Overview: Many trials are now underway to find an effective treatment for COVID-19. To show effectiveness of a treatment a number of endpoints can be considered including duration of hospitalization, ventilator use, mortality etc. Is there a preference? Does it depend n the phase of the study?
In this webinar we discussed the issue of selection of suitable endpoints in the context of recent regulatory guidance documents. We will also touch upon the related study design and analytical issues.
What was covered in the webinar: